The FDA panel upheld the formulated BPC-157, KPV peptide, in RFK Jr.’s victory.

Lizzy leads STAT’s FDA coverage. Her story explores the relationship between politics and science at the FDA, its influence on industry, and the agency’s ability to protect and promote public health. Sensitive information can be sent on Signal at lizzylaw.53.

In a victory for peptide advocates and Health Secretary Robert F. Kennedy Jr., an advisory committee to the Food and Drug Administration recommended Thursday that compounding pharmacies be allowed to manufacture the drugs BPC-157, KPV, TB-500, and MOTS-c.

The FDA committee is scheduled to vote on additional compounds on Friday.

The vote is non-binding, and the FDA will ultimately decide whether to lift current restrictions on these peptides and make them more readily available to people who are turning to little-researched but highly popular drugs to improve their health. It is unusual for the FDA to go against the recommendations of the Pharmacy Compounding Advisory Committee (PCAC), but it has happened at least once in the past.

STAT+ exclusive story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Subscribe to STAT+ for this article and daily biotech coverage and analysis.

Already have an account? Log in

Individual plan Group plan See all plans

To read the rest of this story, subscribe to STAT+.

Subscribe



Source link